REG - Diaceutics PLC - New Service Launched & First Contract Signed

DiaceuticsAnnouncement

08/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250108:nRSH4852Sa&default-theme=true

RNS Number : 4852S  Diaceutics PLC  08 January 2025

Diaceutics Launches New Service and Signs First Contract for up to $1.8m

 

New Pathology Engagement Liaisons service (PEL) launched

 

PEL will augment the suite of services available under Diaceutics' PMx
commercialisation solution and increase the available revenue per brand for
Diaceutics

 

Belfast and London, 8 January 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, is pleased to announce that it
has launched its new Pathology Engagement Liaisons (PEL) service and secured
its first contract worth up to $1.8 million over 12 months. The new contract
is with an existing customer ("the Customer"), a top twenty global pharma
company, and will facilitate the outreach and education of laboratory
pathologists for pancreatic cancer testing in the US market.

 

There are limited options currently available that enable pharma companies to
engage directly with laboratories and pathologists at scale. The launch of PEL
will allow Diaceutics to utilise the DXRX platform and its laboratory network
to engage pathologists in biomarker testing and diagnostic focused education,
supporting best in class biomarker-test-adoption and implementation within
laboratories globally.

 

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented:
"It is very exciting to continue to build our product utilising the DXRX lab
network in the US. More importantly, this engagement will make a significant
difference to patient lives with us working closely with our pharma customer
to bring this new therapy option to patients in need".

 

This first contract win will see Diaceutics roll out PEL across existing DXRX
network laboratories in the US to support the outreach and engagement of
pathologists performing immunohistochemistry testing for pancreatic cancer
patients. This will drive biomarker education, testing and awareness related
to the Customer's newly approved therapy and ultimately, is expected, will
improve patient identification and clinical outcomes.

 

This first contract win for PEL is as a standalone service. However, PEL can
also be deployed under Diaceutics' PMx commercialisation solution, helping to
optimise laboratory testing and patient recruitment to therapy. PEL further
enhances the relevance of Diaceutics' services to therapy brands and increases
the revenue per brand available to Diaceutics.

 

Contract & Terms

This contract extends to the end of 2025 and will be worth up to $1.8 million
in revenue over the term of the contract.

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

 

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of MAR.

The person responsible for making this announcement on behalf of the Company
is Nick Roberts, Chief Financial Officer.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUPUAUGUPAPGM